当前位置:首页 - 行情中心 - 康华生物(300841) - 财务分析 - 现金流量表

康华生物

(300841)

  

流通市值:66.72亿  总市值:71.31亿
流通股本:1.22亿   总股本:1.30亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金548,424,276.75233,324,058.561,280,378,702.88863,856,151.93
  收到的税费返还---66,300
  收到其他与经营活动有关的现金26,562,196.7223,056,630.5416,842,191.3510,429,261.13
  经营活动现金流入小计574,986,473.47256,380,689.11,297,220,894.23874,351,713.06
  购买商品、接受劳务支付的现金22,731,713.144,836,327.1333,407,620.4528,640,735.26
  支付给职工以及为职工支付的现金82,935,284.0352,353,563.73152,471,745.48127,322,820.24
  支付的各项税费69,798,717.4729,478,284.1471,753,965.4654,708,308.74
  支付其他与经营活动有关的现金238,023,105.09148,839,837.28659,877,277.8509,954,643.94
  经营活动现金流出小计413,488,819.73235,508,012.28917,510,609.19720,626,508.18
  经营活动产生的现金流量净额161,497,653.7420,872,676.82379,710,285.04153,725,204.88
二、投资活动产生的现金流量:
  收回投资收到的现金1,181,593,025.57451,000,0001,018,315,350.17515,768,711.84
  取得投资收益收到的现金4,850,440.531,172,423.219,749,660.654,602,005
  处置固定资产、无形资产和其他长期资产收回的现金净额--67,869.4617,500
  投资活动现金流入小计1,186,443,466.1452,172,423.211,028,132,880.28520,388,216.84
  购建固定资产、无形资产和其他长期资产支付的现金13,158,391.788,568,041.2270,785,928.948,071,836.07
  投资支付的现金1,906,000,000992,000,000810,000,000560,000,000
  支付其他与投资活动有关的现金70,000,000---
  投资活动现金流出小计1,989,158,391.781,000,568,041.22880,785,928.9608,071,836.07
  投资活动产生的现金流量净额-802,714,925.68-548,395,618.01147,346,951.38-87,683,619.23
三、筹资活动产生的现金流量:
  取得借款收到的现金--179,793,800149,793,800
  筹资活动现金流入平衡项目--00
  筹资活动现金流入小计--179,793,800149,793,800
  偿还债务支付的现金139,793,800109,793,800226,784,905.68186,784,905.68
  分配股利、利润或偿付利息支付的现金65,489,523.78393,940.04136,430,355.71135,686,621.95
  筹资活动现金流出小计205,283,323.78110,187,740.04363,215,261.39322,471,527.63
  筹资活动产生的现金流量净额-205,283,323.78-110,187,740.04-183,421,461.39-172,677,727.63
四、汇率变动对现金及现金等价物的影响-28,086.65-14,104.0943,743.355,411.6
五、现金及现金等价物净增加额-846,528,682.37-637,724,785.32343,679,518.33-106,580,730.38
  加:期初现金及现金等价物余额1,143,392,808.71,143,392,808.7799,713,290.37799,713,290.37
  期末现金及现金等价物余额296,864,126.33505,668,023.381,143,392,808.7693,132,559.99
补充资料:
  净利润141,149,300.39-219,897,935.04-
  资产减值准备15,191,425.97-8,089,709.48-
  固定资产和投资性房地产折旧35,437,708.05-72,760,457.82-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧35,437,708.05-72,760,457.82-
  无形资产摊销1,597,237.42-4,008,303.32-
  长期待摊费用摊销8,437,677.67-11,753,812.35-
  处置固定资产、无形资产和其他长期资产的损失--8,912.45-
  固定资产报废损失142,570.19-121,629.93-
  公允价值变动损失-4,558,765.9-3,572,949.83-
  财务费用370,511.22-3,637,284.9-
  投资损失-2,515,393.46--5,433,347.58-
  递延所得税-1,516,212.93--4,780,003.24-
  其中:递延所得税资产减少-1,558,512.93--4,780,003.24-
    递延所得税负债增加42,300---
  存货的减少7,730,668.59-27,985,503.4-
  经营性应收项目的减少-82,757,877.97-64,310,437.57-
  经营性应付项目的增加42,788,804.5--37,732,386.58-
  现金的期末余额296,864,126.33-1,143,392,808.7-
  减:现金的期初余额1,143,392,808.7-799,713,290.37-
  现金及现金等价物的净增加额-846,528,682.37-343,679,518.33-
公告日期2026-08-182026-04-212026-04-212025-10-17
审计意见(境内)标准无保留意见
TOP↑